Rapid Skeletal Muscle Loss Tracks a Dangerous Cirrhosis Phenotype
A new cohort study in cirrhosis puts hard numbers on a process clinicians recognize at the bedside but rarely measure with precision: progressive skeletal muscle wasting while patients wait for liver transplantation. Among ambulatory adults followed at a tertiary center, the median annualized change in skeletal muscle index was modestly negative overall, but a substantial subgroup lost muscle quickly enough to separate into a distinctly higher-risk clinical category.
The study used serial abdominal CT scans to quantify skeletal muscle index at the L3 level, then normalized those values for height and converted the change into an annualized percent slope. That approach matters because it moves muscle loss from a vague impression to a measurable trajectory. In chronic liver disease, sarcopenia is not just a nutritional marker; it reflects a combined burden of portal hypertension, inflammation, impaired protein synthesis, catabolic stress, and declining physiologic reserve. Once that reserve erodes, the patient may remain ambulatory for a time while quietly crossing into a narrower transplant window.
A Measurable Decline in Muscle Became a Prognostic Signal
The cohort included 364 patients with a median age of 62 years, 68% male, and a median MELD-Na of 12. Baseline severity was therefore not extreme in most participants, yet the muscle trajectory still diverged. The median annualized percent change in skeletal muscle index was -1.6%, with an interquartile range from -7.4% to +3.7%. Even within that spread, the tail of the distribution carried clinical weight: rapid muscle loss was defined as the worst quartile of change, corresponding to an annualized decline below -7.4%.
One hundred and ninety-one? No — 91 patients fell into that rapid loss group. The rest did not. The distinction was not academic. Patients with rapid muscle loss had markedly worse waitlist survival than those without it, with cumulative mortality or delisting for being too ill for transplantation reaching 32% at 12 months and 75% at 24 months, compared with 10% and 27% in the non-rapid-loss group.
Ascites and Higher MELD-Na Pointed to Faster Catabolism
Two clinical features independently predicted rapid muscle loss: ascites and a higher MELD-Na score. Ascites carried an odds ratio of 1.77 with a 95% confidence interval of 1.00 to 3.12, while MELD-Na carried an odds ratio of 1.06 with a 95% confidence interval of 1.00 to 1.13. Those associations fit the biology of decompensated liver disease. Ascites often signals more advanced portal hypertension, neurohormonal activation, reduced oral intake, and a proinflammatory state that pushes the body toward net protein breakdown. Rising MELD-Na, even within a relatively low median range, likely captures the accumulating burden of hepatic dysfunction that accelerates loss of lean tissue.
The pattern is clinically familiar. Patients with ascites often eat less because of early satiety and abdominal discomfort, while sodium restriction and recurrent hospitalizations can further erode intake. At the same time, cirrhosis shifts fuel handling away from efficient muscle preservation and toward catabolism, making skeletal muscle an energy reservoir the body increasingly consumes when hepatic function worsens. Once muscle is lost, ammonia handling and physical resilience can deteriorate as well, creating a feedback loop that affects both daily function and transplant candidacy.
Waitlist Mortality Diverged Sharply Once Muscle Loss Accelerated
The survival curves separated in a way that should be difficult to ignore in transplant clinics. By 12 months, mortality or delisting among rapid-loss patients was more than triple that of their peers. By 24 months, the gap widened further, with three quarters of the rapid-loss group reaching the composite endpoint versus just over one quarter of patients without rapid muscle loss. Those figures suggest that longitudinal muscle decline is not simply a background feature of cirrhosis; it is a marker of impending clinical instability.
This is where serial imaging becomes more than a retrospective research tool. Abdominal CT scans are already being obtained for many patients awaiting transplantation, often for routine surveillance or procedural planning. Measuring skeletal muscle from those scans could help identify patients whose physiologic decline outpaces what MELD-Na alone conveys. In a disease where the transplant list is structured around organ failure severity, muscle trajectory may expose another layer of risk — one that predicts who is sliding toward delisting before they appear overtly too sick on standard labs.
Serial CT May Capture a Transplant-Relevant Frailty Metric
The use of at least two CT scans between February 2015 and January 2021 allowed the investigators to estimate change over time rather than relying on a single cross-sectional snapshot. That is a major strength in cirrhosis, where one-time body composition measures can miss the direction of travel. A patient can look stable on a single image while losing lean mass fast enough to alter prognosis within months.
The broader implication is practical: skeletal muscle loss may function as a dynamic biomarker of frailty in cirrhosis, complementing MELD-Na and clinical exam. Transplant teams already consider nutrition, ascites control, and functional capacity, but a quantifiable muscle slope could sharpen those judgments. It may also help identify patients who need more aggressive nutrition support, earlier physical rehabilitation, ascites management, or closer transplant surveillance before the decline becomes irreversible.
What the Cohort Can and Cannot Prove
This was a single-center cohort of ambulatory adults awaiting liver transplantation, so the findings apply most directly to a transplant-evaluation population rather than to all people with cirrhosis. The design also shows association, not causation. Rapid muscle loss may be a marker of deeper illness rather than a direct driver of mortality, even though the biology strongly suggests the two are intertwined.
Still, the message is hard to miss. In cirrhosis, skeletal muscle can fall quickly enough to alter the odds of surviving to transplant. When ascites and rising MELD-Na accompany that loss, the patient’s trajectory can worsen long before the endpoint becomes obvious on routine labs or a bedside exam.